Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 15;196(43):E1429-E1431.
doi: 10.1503/cmaj.241426-f.

Place à un meilleur traitement de l’insuffisance cardiaque

[Article in French]
Jonathan Howlett  1
Affiliations

Place à un meilleur traitement de l’insuffisance cardiaque

[Article in French]
Jonathan Howlett. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Intérêts concurrents :: Le Dr Jonathan Howlett déclare avoir reçu des bourses de recherche des sociétés Novo Nordisk, Merck et AstraZeneca, et avoir offert des services conseils aux sociétés Novo Nordisk et Bayer. Il a aussi fourni des témoignages d’expert rémunérés au Alberta College of Physicians and Surgeons et à l’Association canadienne de protection médicale. Enfin, il préside le Comité des lignes directrices de la Société cardiovasculaire du Canada. Aucun autre intérêt concurrent n’a été déclaré.

References

    1. Van MT, Loewen P, Sadatsafavi M. Pharmacotherapy sequencing strategies for patients with heart failure with reduced ejection fraction: a cost–utility analysis. CMAJ 2024;196:E1221–31.
    1. Shahim B, Kapelios CJ, Savarese G, et al. . Global public health burden of heart failure: an updated review. Card Fail Rev 2023;9:e11. doi : 10.15420/cfr.2023.05. - DOI - PMC - PubMed
    1. McDonald M, Virani S, Chan M, et al. . CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 2021;37:531–46. - PubMed
    1. Vaduganathan M, Claggett BL, Jhund PS, et al. . Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396:121–8. - PubMed
    1. Miller RJ, Howlett JG, Fine NM. A novel approach to medical management of heart failure with reduced ejection fraction. Can J Cardiol 2021;37:632–43. - PubMed

LinkOut - more resources